Literature DB >> 22530954

Comparison of dynamics of extracellular accesses to the β(1) and β(2) adrenoceptors binding sites uncovers the potential of kinetic basis of antagonist selectivity.

Balaji Selvam1, Jeff Wereszczynski, Irina G Tikhonova.   

Abstract

From the molecular mechanism of antagonist unbinding in the β(1) and β(2) adrenoceptors investigated by steered molecular dynamics, we attempt to provide further possibilities of ligand subtype and subspecies selectivity. We have simulated unbinding of β(1)-selective Esmolol and β(2)-selective ICI-118551 from both receptors to the extracellular environment and found distinct molecular features of unbinding. By calculating work profiles, we show different preference in antagonist unbinding pathways between the receptors, in particular, perpendicular to the membrane pathway is favourable in the β(1) adrenoceptor, whereas the lateral pathway involving helices 5, 6 and 7 is preferable in the β(2) adrenoceptor. The estimated free energy change of unbinding based on the preferable pathway correlates with the experimental ligand selectivity. We then show that the non-conserved K347 (6.58) appears to facilitate in guiding Esmolol to the extracellular surface via hydrogen bonds in the β(1) adrenoceptor. In contrast, hydrophobic and aromatic interactions dominate in driving ICI-118551 through the easiest pathway in the β(2) adrenoceptor. We show how our study can stimulate design of selective antagonists and discuss other possible molecular reasons of ligand selectivity, involving sequential binding of agonists and glycosylation of the receptor extracellular surface.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22530954      PMCID: PMC3399986          DOI: 10.1111/j.1747-0285.2012.01390.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  39 in total

Review 1.  Steered molecular dynamics and mechanical functions of proteins.

Authors:  B Isralewitz; M Gao; K Schulten
Journal:  Curr Opin Struct Biol       Date:  2001-04       Impact factor: 6.809

2.  Glycosylation affects agonist binding and signal transduction of the rat somatostatin receptor subtype 3.

Authors:  R B Nehring; D Richter; W Meyerhof
Journal:  J Physiol Paris       Date:  2000 May-Aug

3.  Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.

Authors:  C Hoffmann; M R Leitz; S Oberdorf-Maass; M J Lohse; K-N Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-17       Impact factor: 3.000

4.  Beta(1)-selective agonist (-)-1-(3,4-dimethoxyphenetylamino)-3-(3,4-dihydroxy)-2-propanol [(-)-RO363] differentially interacts with key amino acids responsible for beta(1)-selective binding in resting and active states.

Authors:  Yoshiyuki Sugimoto; Reiko Fujisawa; Ryuji Tanimura; Anne Laure Lattion; Susanna Cotecchia; Gozoh Tsujimoto; Taku Nagao; Hitoshi Kurose
Journal:  J Pharmacol Exp Ther       Date:  2002-04       Impact factor: 4.030

Review 5.  Modulation of beta-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action.

Authors:  M Zaugg; M C Schaub; T Pasch; D R Spahn
Journal:  Br J Anaesth       Date:  2002-01       Impact factor: 9.166

6.  Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.

Authors:  M Isogaya; Y Sugimoto; R Tanimura; R Tanaka; H Kikkawa; T Nagao; H Kurose
Journal:  Mol Pharmacol       Date:  1999-11       Impact factor: 4.436

7.  Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states.

Authors:  Gayathri Swaminath; Yang Xiang; Tae Weon Lee; Jacqueline Steenhuis; Charles Parnot; Brian K Kobilka
Journal:  J Biol Chem       Date:  2003-10-14       Impact factor: 5.157

8.  A primate-dominant third glycosylation site of the beta2-adrenergic receptor routes receptors to degradation during agonist regulation.

Authors:  Jeanne Mialet-Perez; Stuart A Green; William E Miller; Stephen B Liggett
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

9.  Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist.

Authors:  Graham P Jackman; Dimitri Iakovidis; Tracy L Nero; Nagesh S Anavekar; Linda A Rezmann-Vitti; Simon N S Louis; Masanori Mori; Olaf H Drummer; William J Louis
Journal:  Eur J Med Chem       Date:  2002-09       Impact factor: 6.514

10.  Glycosylation of beta(1)-adrenergic receptors regulates receptor surface expression and dimerization.

Authors:  Junqi He; Jianguo Xu; Amanda M Castleberry; Anthony G Lau; Randy A Hall
Journal:  Biochem Biophys Res Commun       Date:  2002-09-27       Impact factor: 3.575

View more
  6 in total

Review 1.  What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?

Authors:  Mayako Michino; Thijs Beuming; Prashant Donthamsetti; Amy Hauck Newman; Jonathan A Javitch; Lei Shi
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 2.  β-Adrenergic receptor, an essential target in cardiovascular diseases.

Authors:  Daniel Chikere Ali; Muhammad Naveed; Andrew Gordon; Fatima Majeed; Muhammad Saeed; Michael I Ogbuke; Muhammad Atif; Hafiz Muhammad Zubair; Li Changxing
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 3.  Beyond standard molecular dynamics: investigating the molecular mechanisms of G protein-coupled receptors with enhanced molecular dynamics methods.

Authors:  Jennifer M Johnston; Marta Filizola
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

4.  Exploring the kinetic selectivity of drugs targeting the β1 -adrenoceptor.

Authors:  David A Sykes; Mireia Jiménez-Rosés; John Reilly; Robin A Fairhurst; Steven J Charlton; Dmitry B Veprintsev
Journal:  Pharmacol Res Perspect       Date:  2022-08

5.  Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease.

Authors:  Caterina Branca; Elena V Wisely; Lauren K Hartman; Antonella Caccamo; Salvatore Oddo
Journal:  Neurobiol Aging       Date:  2014-06-16       Impact factor: 4.673

6.  Simulations of biased agonists in the β(2) adrenergic receptor with accelerated molecular dynamics.

Authors:  Irina G Tikhonova; Balaji Selvam; Anthony Ivetac; Jeff Wereszczynski; J Andrew McCammon
Journal:  Biochemistry       Date:  2013-08-07       Impact factor: 3.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.